National Cancer Institute (NCI): Breast Neoplasms, Male trials

The registry lists 47 Breast Neoplasms, Male studies with National Cancer Institute (NCI) as lead sponsor. 0 are open to participants now and 17 have results posted.

Phase 1 27Phase 2 26Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Azacitidine and Entinostat in Treating Patients With Advanced Breast CancerCompletedNCT01349959Phase 2Results posted
• RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast CancerTerminatedNCT01217411Phase 1/2Results posted
• Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast CancerTerminatedNCT01151449Phase 2Results posted
• Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by SurgeryCompletedNCT00861705Phase 2Results posted
• Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by SurgeryCompletedNCT00770809Phase 3Results posted
• Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast CancerCompletedNCT00699491Phase 1/2Results posted
• Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By SurgeryCompletedNCT00559507Phase 2Results posted
• Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast CancerCompletedNCT00470301Phase 1/2Results posted
• Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast CancerCompletedNCT00368875Phase 1/2Results posted
• Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast CancerCompletedNCT00258349Phase 1/2Results posted
• A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)CompletedNCT00244881Phase 2Results posted
• Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast CancerTerminatedNCT00132002Phase 2Results posted
• Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast CancerCompletedNCT00119262Phase 2Results posted
• Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous TamoxifenCompletedNCT00118157Phase 2Results posted
• Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast CancerCompletedNCT00077376Phase 2Results posted
• GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast CancerCompletedNCT00068588Phase 2Results posted
• Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast CancerTerminatedNCT00063934Phase 1/2Results posted
• Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By SurgeryTerminatedNCT01705340Phase 1
• Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast CancerCompletedNCT01624441Phase 1
• Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT01281150Phase 1
• Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by SurgeryCompletedNCT01276496Phase 1
• Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast CancerCompletedNCT01245205Phase 1
• RO4929097 and Capecitabine in Treating Patients With Refractory Solid TumorsCompletedNCT01158274Phase 1
• RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast CancerTerminatedNCT01149356Phase 1
• Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast CancerCompletedNCT01145430Phase 1
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsCompletedNCT01131234Phase 1
• Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung CancerTerminatedNCT00937482Phase 1
• Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By SurgeryTerminatedNCT00450879Phase 1
• AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By SurgeryCompletedNCT00348699Phase 1
• Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain MetastasesCompletedNCT00098605Phase 2
• FR901228 in Treating Patients With Metastatic Breast CancerCompletedNCT00098397Phase 2
• Sorafenib in Treating Patients With Metastatic Breast CancerCompletedNCT00096434Phase 2
• 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast CancerTerminatedNCT00095888Phase 2
• Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00089362Phase 1
• Vaccine Therapy in Treating Patients With Metastatic Breast CancerTerminatedNCT00071942Phase 1
• Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast CancerCompletedNCT00070252Phase 1/2
• Imatinib Mesylate in Treating Patients With Metastatic Breast CancerCompletedNCT00045188Phase 2
• Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast CancerTerminatedNCT00039455Phase 1
• Decitabine in Treating Patients With Advanced Solid TumorsCompletedNCT00030615Phase 1
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid TumorsCompletedNCT00028535Phase 1
• Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic CancerCompletedNCT00028496Phase 1
• Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast CancerCompletedNCT00024154Phase 2
• Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast CancerCompletedNCT00017394Phase 2
• Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast CancerCompletedNCT00006228Phase 2
• Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast CancerCompletedNCT00005817Phase 2
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1